Patents by Inventor Meredith Williams

Meredith Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170121332
    Abstract: The present invention relates to a purine compound useful as a kinase inhibitor.
    Type: Application
    Filed: January 9, 2017
    Publication date: May 4, 2017
    Inventors: DiZhong Chen, Meredith Williams
  • Publication number: 20160207927
    Abstract: The present invention relates to a purine compound useful as a kinase inhibitor.
    Type: Application
    Filed: August 18, 2015
    Publication date: July 21, 2016
    Inventors: DiZhong Chen, Meredith Williams
  • Patent number: 9138437
    Abstract: The present invention relates to a purine compound useful as a kinase inhibitor. The compound has the structure: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: September 22, 2015
    Assignee: Verastem, Inc.
    Inventors: DiZhong Chen, Meredith Williams
  • Publication number: 20150105382
    Abstract: The present invention relates to a purine compound useful as a kinase inhibitor.
    Type: Application
    Filed: May 7, 2014
    Publication date: April 16, 2015
    Applicant: VERASTEM, INC.
    Inventors: DiZhong Chen, Meredith Williams
  • Patent number: 8754080
    Abstract: The present invention relates to a purine compound useful as a kinase inhibitor. The compound has the structure (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: June 17, 2014
    Assignee: Verastem, Inc.
    Inventors: DiZhong Chen, Meredith Williams
  • Patent number: 8686011
    Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: April 1, 2014
    Assignees: Amgen Inc., Biovitrum AB
    Inventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, Jr., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle
  • Publication number: 20140066620
    Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.
    Type: Application
    Filed: November 11, 2013
    Publication date: March 6, 2014
    Applicant: VERASTEM, INC.
    Inventors: Harish K. Mysore, Meredith Williams
  • Patent number: 8609838
    Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumors and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 17, 2013
    Assignee: Verastem, Inc.
    Inventors: Harish K. Nagaraj, Meredith Williams
  • Patent number: 8541592
    Abstract: The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: September 24, 2013
    Assignees: Amgen Inc., Biovitrum AB
    Inventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, Jr., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle, Teresa L. Marshall
  • Publication number: 20130231971
    Abstract: A computer-implemented system for developing, tracking and managing legal (and other professional services) projects or matters through the Legal Project Management (LPM) process. The LPM process divides the management of a legal matter or project into three phases: Project Development; Project Execution; and Project Closure. The Project Development Phase includes conflict screening, fee arrangements, identification of the nature and scope of the matter, the goals of the stakeholders, the tasks associated with the matter, and development of a schedule, budget, and a communications plan. The Project Execution Phase involves monitoring the progress of the matter, tracking the actual time and cost to budget, identifying risks and changes to the scope of the matter as they develop, and communicating among team members. The Project Closure Phase includes file closure procedures, and team and client meetings to identify lessons learned in the engagement for future improvement.
    Type: Application
    Filed: August 23, 2012
    Publication date: September 5, 2013
    Inventors: JUDY BISHOP, Mike Burks, John Christenson, Paul Davis, Felicia Morris, William Painter, Jennifer Reese, David Rueff, Meredith Williams, Conda Winchester
  • Publication number: 20130079512
    Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.
    Type: Application
    Filed: July 20, 2012
    Publication date: March 28, 2013
    Applicant: Verastem
    Inventors: Harish K. Nagaraj, Meredith Williams
  • Patent number: 8247410
    Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumors and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: August 21, 2012
    Assignee: Verastem
    Inventors: Harish K. Nagaraj, Meredith Williams
  • Publication number: 20120142683
    Abstract: The present invention relates to a purine compound useful as a kinase inhibitor.
    Type: Application
    Filed: April 3, 2009
    Publication date: June 7, 2012
    Applicant: S*BIO Pte Ltd.
    Inventors: DiZhong Chen, Meredith Williams
  • Publication number: 20120010256
    Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.
    Type: Application
    Filed: September 15, 2011
    Publication date: January 12, 2012
    Inventors: Martin HENRIKSSON, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, JR., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle
  • Publication number: 20110105500
    Abstract: The present invention relates to purine compounds of formula (I) that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3K and/or mTOR kinases.
    Type: Application
    Filed: June 25, 2009
    Publication date: May 5, 2011
    Applicant: S*BIO Pte Ltd.
    Inventors: Harish Kumar Mysore Nagaraj, Meredith Williams, Chang Kai Soh
  • Publication number: 20110082107
    Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.
    Type: Application
    Filed: October 5, 2010
    Publication date: April 7, 2011
    Inventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J.St. Jean, JR., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle
  • Publication number: 20110009403
    Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with mTOR kinases.
    Type: Application
    Filed: October 3, 2008
    Publication date: January 13, 2011
    Applicant: S*BIO Pte Ltd.
    Inventors: Harish Kumar Mysore Nagaraj, DiZhong Chen, Anders Poulsen, Meredith Williams
  • Publication number: 20100298319
    Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.
    Type: Application
    Filed: October 3, 2008
    Publication date: November 25, 2010
    Applicant: S*BIO Pte Ltd.
    Inventors: Harish Kumar Mysore Nagaraj, Meredith Williams
  • Patent number: 7807700
    Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: October 5, 2010
    Assignee: Amgen Inc.
    Inventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, Jr., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle
  • Publication number: 20080045503
    Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.
    Type: Application
    Filed: June 28, 2007
    Publication date: February 21, 2008
    Inventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric Bercot, Christopher Fotsch, Aiwen Li, Guolin Cai, Randall Hungate, Chester Yuan, Christopher Tegley, David St. Jean, Nianhe Han, Qi Huang, Qingyian Liu, Michael Bartberger, George Moniz, Matthew Frizzle